# US 2024/0174990 A1 · Reverse transcriptase variants

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0174990 A1
- Document ID: US20240174990A1
- Status: Published application
- Kind: A1
- Application number: 18/440,901
- Filed: 2024-02-13
- Published: 2024-05-30
- Earliest claimed: 2019-12-11
- Assignees: 10x Genomics, Inc.
- Applicants: 10x Genomics, Inc.
- Inventors: Sonya A. CLARK; Derek Hunter VALLEJO; Carolina CUELLAR; Katherine PFEIFFER
- Web page: https://patentgrep.com/patent/US20240174990A1

## CPC

- C12N 9/1241: {Nucleotidyltransferases (2.7.7)}
- C12N 9/1276: {RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase}
- C12Y 207/07049: RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The application provides compositions including engineered reverse transcriptases with at least one altered reverse-transcriptase related activity. The engineered reverse transcriptases or reverse transcription enzymes unexpectedly exhibit one or more altered reverse transcriptase related activities such as but not limited to altered template switching efficiency, altered transcription efficiency or both.

## Claims

### Claim at position 1

-17. (canceled)

### Claim 18

A method for performing a reverse transcription reaction, the method comprising:
(i) contacting a template nucleic acid molecule with an engineered reverse transcriptase and a plurality of nucleic acid barcoded molecules, wherein each nucleic acid barcoded molecule comprises a barcode sequence;
(ii) incubating the template nucleic acid molecule, the engineered reverse transcriptase, and the plurality of nucleic acid barcoded molecules under suitable conditions in which the plurality of nucleic acid barcoded molecules are extended by the engineered reverse transcriptase; and
(iii) generating a polymerized nucleic acid product,
wherein the engineered reverse transcriptase comprises a combination of mutations in the amino acid sequence of SEQ ID NO: 18, and wherein the combination of mutations comprises:
(a) E69K, L139P, D200N, E302R, T306K, W313F, T330P, L435K, P448A, D449G, N454K, D524N, L603W, E607K; and
(b) one or more of A32V, M39V, M66L, L72R, L139P, F155Y, D200C, D200E, E201Q, H204R, G248C, E286R, T287A, Y344L, I347L, W388R, R411F, K435G, H503V, D583N, H594K, H594Q, L603F, E607G, H634Y, G637R, H638G, D653H, and L671P.

### Claim at position 3

-20. (canceled)

### Claim 21 (depends on 18)

The method of claim 18, wherein the template nucleic acid is an RNA, a DNA, or a nucleic acid comprising an unnatural nucleotide.

### Claim 22 (depends on 21)

The method of claim 21, wherein the RNA is a mRNA.

### Claim 23 (depends on 18)

The method of claim 18, wherein the polymerized nucleic acid product is a complementary DNA (cDNA) molecule.

### Claim 24 (depends on 18)

The method of claim 18, further comprising H503V, or H634Y.

### Claim 25 (depends on 18)

The method of claim 18, wherein the engineered reverse transcriptase comprises M66L, E69K, L139P, D200N, E302R, T306K, W313F, T330P, P448A, D449G, N454K, L603W and E607K.

### Claim 26 (depends on 18)

The method of claim 18, wherein the engineered reverse transcriptase comprises E69K, L139P, D200N, E302R, T306K, W313F, T330P, P448A, D449G, N454K, H503V, L603W and E607K.

### Claim 27 (depends on 18)

The method of claim 18, wherein the engineered reverse transcriptase comprises E69K, L139P, D200N, E302R, T306K, W313F, T330P, P448A, D449G, N454K, L603W, E607K and H634Y.

### Claim 28 (depends on 18)

The method of claim 18, further comprising H503V and H634Y.

### Claim 29 (depends on 18)

The method of claim 18, wherein the engineered reverse transcriptase comprises L139P, D200N, T330P, L603W, and E607K, and further comprises a second combination of mutations selected from the group consisting of:
(a) M39V mutation, an E69K mutation, an E302R mutation, a T306K mutation, a W313F mutation, a K435G mutation, a P448A mutation, a D449G mutation, and an N454K mutation (AA);
(b) an M66L mutation, an E69K mutation, an E302R mutation, a T306K mutation, a W313F mutation, a K435G mutation, a P448A mutation, a D449G mutation, and an N454K mutation (AB);
(c) a M39V mutation, an M66L mutation, an E69K mutation, an E302R mutation, a T306K mutation, a W313F mutation, a K435G mutation, a P448A mutation, a D449G mutation, and an N454K mutation (AC);
(d) a M39V mutation, an M66L mutation, an E69K mutation, an E201Q mutation, E302R mutation, a T306K mutation, a W313F mutation, a K435G mutation, a P448A mutation, a D449G mutation, an N454K mutation, an FI503V mutation, an FI594K mutation, and an FI634Y mutation (AD);
(e) an E69K mutation, an E201Q mutation, a T287A mutation, E302R mutation, a T306K mutation, a W313F mutation, a K435G mutation, a P448A mutation, a D449G mutation, an N454K mutation, (AE);
(f) an M39V mutation, an M66L mutation, an E69K mutation, an E201Q mutation, a T287A mutation, E302R mutation, a T306K mutation, a W313F mutation, a C409S mutation, a K435G mutation, a P448A mutation, a D449G mutation, an N454K mutation, an H503V mutation, an H594K mutation, and an H634Y mutation (AF);
(g) an E69K mutation, an E201Q mutation, a T287A mutation, E302R mutation, a T306K mutation, a W313F mutation, a C409S mutation, a K435G mutation, a P448A mutation, a D449G mutation, an N454K mutation, and an FI634Y mutation (AG);
(h) an E69K mutation, an E201Q mutation, an E302R mutation, a T306K mutation, a W313F mutation, a K435G mutation, a P448A mutation, a D449G mutation, and an N454K mutation, (AH);
(i) an E69K mutation, a T287A mutation, an E302R mutation, a T306K mutation, a W313F mutation, a K435G mutation, a P448A mutation, a D449G mutation, and an N454K mutation (AI);
(j) an E69K mutation, an E201Q mutation, a T287A mutation, an E302R mutation, a T306K mutation, a W313F mutation, a K435G mutation, a P448A mutation, a D449G mutation, an N454K mutation, and an FI634Y mutation (AJ);
(k) an E69K mutation, an E201Q mutation, a T287A mutation, an E302R mutation, a T306K mutation, a W313F mutation, a K435G mutation, a P448A mutation, a D449G mutation, an N454K mutation, an FI503V mutation, an FI594K mutation, and an FI634Y mutation (AK);
(l) an M39V mutation, an M66L mutation, an E69K mutation, an E201Q mutation, a T287A mutation, an E302R mutation, a T306K mutation, a W313F mutation, an R411F mutation, a K435G mutation, a P448A mutation, a D449G mutation, an N454K mutation, an FI503V mutation, an FI594K mutation, an FI634Y mutation, and a G637R mutation (AL);
(m) a M66L mutation, an E69K mutation, an E302R mutation, a T306K mutation, a W313F mutation, an N454K mutation, an FI503V mutation, and an FI634Y mutation (AM);
(n) a M39V mutation, an M66L mutation, an E201Q mutation, a P448A mutation, a D449G mutation, an FI503V mutation, an FI594K mutation, and an FI634Y mutation (AN);
(o) an M39V mutation, an M66L mutation, an E201Q mutation, a T287A mutation, P448A mutation, a D449G mutation, an FI503V mutation, an FI594K mutation, and an FI634Y mutation (AO);
(p) an M39V mutation, an M66L mutation, an E201Q mutation, a T287A mutation, a P448A mutation, a D449G mutation, an FI503V mutation, an FI594K mutation, an FI634Y mutation, a P636FI mutation (AP);
(q) an E69K mutation, an E302R mutation, a T306K mutation, a W313F mutation, an N454K mutation, and an FI503V mutation (AQ);
(r) an FI503V mutation and an FI634Y mutation (AR);
(s) an E69K mutation, an E302R mutation, a T306K mutation, a W313F mutation, a K435G mutation, and an N454K mutation (AV);
(t) an E69K mutation, an E302R mutation, a T306K mutation, a W313F mutation, a K435G mutation, a P448A mutation, a D449G mutation, an N454K mutation, and an FI638G mutation (AW);
(u) an E69K mutation, an F155Y mutation, an E302R mutation, a T306K mutation, a W313F mutation, a K435G mutation, a P448A mutation, a D449G mutation, an N454K mutation, and an FI638G mutation (AX); and
(v) an E69K mutation, an E302R mutation, a T306K mutation, a W313F mutation, a K435G mutation, an N454K mutation, and an FI594K mutation (AY).

### Claim 30 (depends on 18)

The method of claim 18, wherein the engineered reverse transcriptase is encoded by a nucleic acid sequence from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO:
14, SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17.

### Claim 31 (depends on 18)

The method of claim 18, wherein the nucleic acid barcoded molecule further comprises:
(a) a sequence configured to couple to the template nucleic acid molecule and wherein the sequence configured to couple to the template nucleic acid molecule is selected from the group consisting of an oligo(dT) sequence, a random N-mer primer, or a target-specific primer; and/or
(b) a template switching sequence.

### Claim 32 (depends on 31)

The method of claim 31, wherein the template nucleic acid is a mRNA, the sequence configured to couple to the template nucleic acid molecule is an oligo(dT) sequence, and contacting comprises transcribing the mRNA molecule into the cDNA molecule with the oligo(dT) sequence.

### Claim 33 (depends on 18)

The method of claim 18, wherein the template nucleic acid is a mRNA, and contacting comprises performing a template switching reaction, thereby generating the polymerized nucleic acid product, wherein the polymerized nucleic acid product is a cDNA comprising a nucleic acid barcoded sequence, or a derivative thereof.

### Claim 34 (depends on 18)

The method of claim 18, wherein the contacting step occurs:
(i) in a partition having a reaction volume;
(ii) in a bulk reaction;
(iii) on a nucleic acid array; and/or
(iv) in a reaction volume.

### Claim 35 (depends on 34)

The method of claim 34, wherein:
(a) the reaction volume is less than 1 nanoliter, less than 750 picoliters, or less than 500 picoliters; or
(b) the partition is a droplet or well.

### Claim 36 (depends on 18)

The method of claim 18, wherein the method is performed at a temperature of at least about 53° C., at least about 70° C., at least about 80° C., at least about 90° C., or between about 70° C. to about 90° C.

### Claim 37 (depends on 33)

The method of claim 33, wherein the engineered reverse transcriptase is encoded by the nucleic acid sequence SEQ ID NO: 4 or SEQ ID NO: 17.

### Claim 38

A method for performing a reverse transcription reaction using an engineered reverse transcriptase, the method comprising:
(a) providing a reaction volume comprising an engineered reverse transcriptase, a template ribonucleic acid (RNA) molecule, and a plurality of nucleic acid barcoded molecules,
wherein the reaction volume is less than 1 nanoliter, and
wherein the engineered reverse transcriptase is encoded by the nucleic acid sequence of SEQ ID NO: 4 or SEQ ID NO: 17;
(b) contacting the template RNA molecule with the engineered reverse transcriptase and the plurality of nucleic acid barcoded molecules, wherein each nucleic acid barcoded molecule comprises a barcode sequence;
(c) incubating the template RNA molecule, the engineered reverse transcriptase, and the plurality of nucleic acid barcoded molecules under suitable conditions in which the plurality of nucleic acid barcoded molecules are extended by the engineered reverse transcriptase; and
(d) generating a complementary DNA (cDNA) molecule.

### Claim 39 (depends on 38)

The method of claim 38, wherein the method is performed at a temperature of at least about 53° C.
